BACKGROUND: A New Zealand serogroup B meningococcal epidemic prompted trials of a strain-specific (B:4:P1.7-2,4) outer membrane vesicle vaccine (MeNZB). METHODS: Adults, school children, and infants provided serum after three MeNZB doses to evaluate antibody persistence via serum bactericidal assay. Toddler (16-24 months) non-responders and responders received a fourth MeNZB dose 11 and 17 months after dose three respectively. Response was a ≥4-fold rise in bactericidal titre to a titre of ≥8. RESULTS: Geometric mean bactericidal titres (GMTs), with 95% CI, after dose 3: adults: 27 (14-52), 5 (3-11), and 7 (3-15) at 1, 10, and 22 months; school children: 18 (13-25) and 4 (3-6) at 1 and 4 months; infants: 27 (19-39) and 2 (2-3) at 1 and 7 months. The titre achieved after priming significantly influenced persistence. Toddler non-responder GMTs were 4 (3-5) and 1 (1-1) at 1 and 11 months after dose 3 and 69 (46-106) 1 month after dose 4. Responder GMTs were 24 (19-30) and 3 (2-4) at 1 and 17 months after dose 3 and 259 (184-363) 1 month after dose 4. Dose 4 had no safety concerns. CONCLUSIONS: Immune response to MeNZB was most sustained in adults. In infants, bactericidal titres decayed almost to baseline by 7 months after dose 3. Toddlers showed marked immune response following a fourth dose suggesting memory. Persisting antibody is likely to be necessary for ongoing protection, as seen with serogroup C meningococci.
BACKGROUND: A New Zealand serogroup B meningococcal epidemic prompted trials of a strain-specific (B:4:P1.7-2,4) outer membrane vesicle vaccine (MeNZB). METHODS: Adults, school children, and infants provided serum after three MeNZB doses to evaluate antibody persistence via serum bactericidal assay. Toddler (16-24 months) non-responders and responders received a fourth MeNZB dose 11 and 17 months after dose three respectively. Response was a ≥4-fold rise in bactericidal titre to a titre of ≥8. RESULTS: Geometric mean bactericidal titres (GMTs), with 95% CI, after dose 3: adults: 27 (14-52), 5 (3-11), and 7 (3-15) at 1, 10, and 22 months; school children: 18 (13-25) and 4 (3-6) at 1 and 4 months; infants: 27 (19-39) and 2 (2-3) at 1 and 7 months. The titre achieved after priming significantly influenced persistence. Toddler non-responder GMTs were 4 (3-5) and 1 (1-1) at 1 and 11 months after dose 3 and 69 (46-106) 1 month after dose 4. Responder GMTs were 24 (19-30) and 3 (2-4) at 1 and 17 months after dose 3 and 259 (184-363) 1 month after dose 4. Dose 4 had no safety concerns. CONCLUSIONS: Immune response to MeNZB was most sustained in adults. In infants, bactericidal titres decayed almost to baseline by 7 months after dose 3. Toddlers showed marked immune response following a fourth dose suggesting memory. Persisting antibody is likely to be necessary for ongoing protection, as seen with serogroup C meningococci.
Authors: Koen B Pouwels; Eelko Hak; Arie van der Ende; Hannah Christensen; Germie P J M van den Dobbelsteen; Maarten J Postma Journal: Hum Vaccin Immunother Date: 2013-02-13 Impact factor: 3.452
Authors: Matthew D Snape; Praveen Saroey; Tessa M John; Hannah Robinson; Sarah Kelly; Nicoletta Gossger; Ly-Mee Yu; Huajun Wang; Daniela Toneatto; Peter M Dull; Andrew J Pollard Journal: CMAJ Date: 2013-09-23 Impact factor: 8.262
Authors: Anke Ziegenbalg; Rafael Prados-Rosales; Elisabeth R Jenny-Avital; Ryung S Kim; Arturo Casadevall; Jacqueline M Achkar Journal: Tuberculosis (Edinb) Date: 2013-04-02 Impact factor: 3.131